Variable number tandem repeats (VNTRs) were among the first genetic markers used to quantitate bone marrow transplant engraftment. STRs, which are standard tools for genotyping in parentage testing 6 and forensic human identity testing, 7 have recently been used for the quantitative analysis of BMT engraftment. [8] [9] [10] [11] STRs provide an excellent tool for this purpose because of their high degree of polymorphism and relatively short length. Furthermore, STR-based human identity kits are commercially available, which eliminates the need for developing the methodology in each individual laboratory. Several of the commercial STR human identity kits have been optimized for automated DNA sequencers which enables data collection and analysis by sophisticated software. Commercial kits for VNTR analysis currently are not available. Although STRs are now widely used in BMT testing, only one direct comparison of VNTR and STR engraftment results has been published.
number tandem repeats (VNTRs), and short tandem repeats (STRs). VNTRs have been used as a reliable method to follow BMT engraftment status, first by Southern analysis and then by PCR. [2] [3] [4] [5] Although VNTRs perform well in the clinical molecular diagnosis laboratory, the limitations of PCR-based VNTR markers in distinguishing some donor/recipient pairs demonstrate the need for additional genetic markers to analyze engraftment.
STRs, which are standard tools for genotyping in parentage testing 6 and forensic human identity testing, 7 have recently been used for the quantitative analysis of BMT engraftment. [8] [9] [10] [11] STRs provide an excellent tool for this purpose because of their high degree of polymorphism and relatively short length. Furthermore, STR-based human identity kits are commercially available, which eliminates the need for developing the methodology in each individual laboratory. Several of the commercial STR human identity kits have been optimized for automated DNA sequencers which enables data collection and analysis by sophisticated software. Commercial kits for VNTR analysis currently are not available. Although STRs are now widely used in BMT testing, only one direct comparison of VNTR and STR engraftment results has been published. 11 The purpose of this study is to validate STRs in BMT engraftment analysis by comparing VNTR and STR results for the same sets of post-transplant samples from patients who had undergone allogeneic BMT. Sixteen post-transplant samples from four allogeneic BMT patients are included in this correlation study. Patient samples previously analyzed by the VNTR method at the FairviewUniversity Medical Center Molecular Diagnostics Laboratory were chosen to cover the full range of engraftment from near 0% to 100%. STR analysis was then performed on the same samples in a blinded fashion at the Central Arkansas Veterans Healthcare System Molecular Diagnostics Laboratory. Good quantitative correlation was found between STR and VNTR results in samples from all four patients. STR markers were informative in one patient for whom PCR-based VNTR markers were not available. This study demonstrates that STR-based human identity testing kits are well suited for engraftment analysis.
Bone Marrow Transplantation

Materials and methods
DNA purification
Genomic DNA was isolated from peripheral blood or bone marrow. Samples were collected in EDTA and extracted by detergent lysis, salt fractionation, and isopropanol precipitation (Puregene DNA Isolation Kit, Gentra Systems, Minneapolis, MN, USA). DNA concentration was measured by UV spectrophotometry at 260 nm.
STR PCR
Multiplex STR analysis was performed with the AmpFlSTR Blue PCR amplification kit (PE Applied Biosystems, Foster City, CA, USA). 12 The kit simultaneously amplifies three autosomal tetranucleotide STR loci with non-overlapping allele size ranges. Loci in the AmpFlSTR Blue kit are D3S1358, vWA and FGA (Table 1) . PCR amplification was performed on a GeneAmp PCR System 9600 thermocycler (PE Applied Biosystems) according to the AmpFlSTR protocol: 20 l DNA template (0.125 ng/l), 21 l AmpFlSTR PCR reaction mix, 11 l AmpFlSTR primer set, and 1 l AmpliTaq Gold DNA polymerase (5 U/l). After amplification, 2.0 l of PCR product was added to a mixture of 4.5 l formamide blue dextran loading buffer and 1.0 l GeneScan 350 ROX (PE Applied Biosystems). The samples were denatured for 5 min at 95°C and then loaded on to a 24 cm long denaturing gel (6.5% acrylamide/7.5 m urea) that was run for 10 h on an ABI 373A DNA Sequencer (Applied Biosystems) in GeneScan collection mode. Fragment size and peak area data were analyzed by GeneScan and GenoTyper software (Applied Biosystems). The AmpFlSTR Blue kit currently is not approved for clinical use by the United States Food and Drug Administration.
VNTR PCR
VNTR PCR loci utilized by the Fairview-University Medical Center Molecular Diagnostics Laboratory in this study are apolipoprotein B (ApoB) 13 and D1S80. 14 PCR was performed with fluorescently labeled oligonucleotide primers specific for the VNTR locus to be amplified. DNA was diluted to 0.06 ng/l for use in PCR. PCR was performed with 250 ng genomic DNA in a 50 l reaction. Each reaction contained 6.25 pmoles of each primer, 0.2 mm dNTPs, 10 mm Tris-HCl (pH 9.0), 50 mm KCl, 0.1% Triton X-100, 1.5 mm MgCl 2 , and 1.25 U Taq polymerase (Promega, Madison, WI, USA). Thermocycling conditions were specific for the VNTR to be amplified. After amplification, 
Calculation of the percentage of donor and recipient DNA
The percentage of donor and recipient DNA can be quantitated by VNTR or STR analysis to estimate the degree of bone marrow engraftment. Peak area ratios (see below) of informative donor and recipient alleles are formulated to express the DNA percentage. Specific formulas for calculating the percentage of donor or recipient DNA are based on whether the informative loci are heterozygous or homozygous and whether the donor and recipient share any alleles. Because recipient DNA is usually the minor component in post-transplant samples, calculation of the percentage of recipient DNA is usually performed. The percentage of donor DNA is then derived by subtracting the percentage of recipient DNA from 100%. In this study, the following two formulas are used to calculate the percentage of recipient DNA where A = peak area; R = recipient allele(s); and D = donor allele(s):
1 Recipient and donor are both heterozygous with no shared alleles:
2 Recipient and donor are both heterozygous with one shared allele [R2 = D2]. The shared allele is omitted from the calculation:
Standard curves
For the STR analysis in this study, standard curves for each donor/recipient pair were generated by mixing known ratios of donor and pre-transplant recipient genomic DNA. The calculated percentages of recipient DNA were then plotted vs the known percentages. Curves were fit by linear regression analysis. Standard curves typically show little deviation from linearity (see Results). For post-transplant sample STR analysis in this study, the percentage of recipient DNA is interpolated from the standard curve. Because replicates were not run, the precision of the assay is not defined and the reported values are considered to be estimates. Standard curves were not generated in this study for VNTR analysis based on an assumption of linearity. The precision of the VNTR assay is not defined and the VNTR results are also considered to be estimates.
Stutter peaks
Stutter peaks are an artifact of STR PCR amplification that may arise from 'slippage' during the PCR process. They consist of small peaks that are one repeat unit shorter than the main amplified peak. Stutter peaks of tetranucleotide STRs are 4 bp shorter than the main peak and usually have a peak area between 5% and 10% of the main peak area. 7 Informative alleles for STR analysis are chosen to avoid stutter peak positions if possible. In cases where an informative allele in a stutter position must be used for post-transplant analysis, contribution from the stutter peak is compensated for by subtraction of a percentage of the main peak area. This percentage is determined by analysis of the relevant stutter peak in the pre-transplant specimen.
Results
Sixteen post-transplant samples from four patients who had undergone allogeneic bone marrow transplantation are included in our correlation study (Table 2 ). Patients are designated by letters A to D. Serial samples were examined STR analysis of the donor and pre-transplant recipient DNA samples was performed to determine the genotype at three loci (D3S1358, vWA and FGA). These genotypes identified informative loci that distinguish the recipient from the donor. Loci are considered to be informative if they show one or more unique alleles for recipient or donor. For all four donor/recipient pairs, at least two loci were informative. Patient A had a total of nine informative alleles (four recipient, five donor) in three loci. Patient B had a total of four informative alleles (two recipient, two donor) in two loci. Patient C had a total of five informative alleles (two recipient, three donor) in three loci. Patient D had a total of six informative alleles (three recipient, three donor) in two loci. The three loci examined therefore contain adequate numbers of informative alleles to perform STR analysis for all donor/recipient pairs.
Recipient post-transplant sample STR results are shown in Table 3 . Thirteen of the 16 samples were quantitated at two independent loci. Three samples were quantitated at a single locus. Values for the same sample determined at independent loci agree closely which demonstrates the internal consistency of the STR multiplex PCR. Although no recipient DNA peak was detected in sample A1, stutter Informative allele is present but percentage could not be calculated because of unusually large stutter peak. NI = no informative recipient allele identified; M = peripheral blood mononuclear cell fraction; G = peripheral blood granulocyte fraction.
peak contributions from donor alleles decreased the threshold of detection such that the STR result is reported as Ͼ98% donor DNA rather than 100%. No stutter peak interference was present in sample B or C. An unusually large stutter peak from shared donor/recipient alleles prevented calculation of the STR value at the FGA locus in sample D. Overall, STR kit performance and internal consistency for the analysis of patient samples are excellent.
For the STR analysis, a standard curve was generated by mixing known ratios of donor and pre-transplant recipient genomic DNA (see Methods). Examples of standard curves determined at two different STR loci for two patients are illustrated ( Figure 1 ). All STR standard curves in this study have regression coefficients Ͼ0.99 by linear least squares analysis. The linearity of these standard curves validates the use of STR analysis for quantitation of mixtures of donor and recipient DNA.
STR results for patient samples are compared with previous VNTR results (Table 4) result is more reliable because it was determined with high precision at two independent loci whereas the VNTR result was determined at a single locus. The correlation curve ( Figure 2) illustrates that the STR results are slightly lower than the corresponding VNTR results. Slight underestimation of the percentage of donor DNA by STR analysis or slight overestimation by VNTR analysis may account for the difference in the STR and VNTR results. Determining which method is more accurate is not possible from this study. Despite the small differences in the donor DNA estimates for the post-transplant samples, the overall correlation of VNTR PCR and STR results is very good. STR markers are informative in one patient (D) for whom PCR-based VNTR markers could not be found. VNTR analysis for patient D had been performed by Southern blot with results for samples D2 and D3 reported as ranges estimated from autoradiography (Table 4) . Sample D1, thought to contain 100% donor DNA by VNTR Southern blot, showed 12% recipient DNA by STR analysis. For sample D2, the STR result is slightly below the range reported from the Southern blot. The STR result for sample D3 is well within the range determined by Southern analysis. Because the VNTR results for patient D are reported in ranges rather than discrete values, correlation data for patient D are not included in Figure 2 . Serial samples from all four patients show decreasing amounts of donor DNA over time. Peak tracings are illustrated for VNTR and STR analyses of serial post-transplant samples from patient C (Figure 3 ). For the ApoB VNTR marker, donor and recipient are both heterozygous with no shared alleles. For the FGA STR marker, donor and recipient are both heterozygous with one shared allele. A decrease in the percentage of donor DNA and concomitant increase in recipient DNA are observed by visual examination of the tracings from the serial samples. This pattern of change is characteristic of failure of engraftment and/or relapse of disease.
Discussion
This correlation study shows very good agreement between VNTR PCR and STR analyses for the same sets of patient post-transplant samples. The agreement in values is similar to the findings reported by others in a correlation study that used different STR loci and an ABI 310 DNA sequencer.
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Because VNTR analysis is a well-established reference method for engraftment analysis, good correlation with VNTR results aids in validating the STR technique and demonstrates that STR analysis is a reliable method for monitoring BMT engraftment.
The availability of commercial multiplex STR kits and the high degree of STR polymorphism assures that at least one informative STR locus will be found for any donor/recipient pair (with the exception of identical twins). In our study, STR markers were informative in one patient for whom PCR-based VNTR markers could not be found. Engraftment analysis for this patient had been performed by Southern blot with a VNTR probe. In one post-transplant sample from this patient, a mixed chimera was identified by the STR method that was not detected by Southern analysis. The use of STRs for engraftment analysis should therefore eliminate the need to perform less accurate and more cumbersome Southern blots as a back-up technique.
One potential problem with STR analysis is stutter peaks, an artifact of STR PCR amplification (see Methods) that may interfere with engraftment analysis. Stutter peaks are not seen in VNTR PCR because of the larger size of the VNTR repeat unit. In STR analysis of BMT engraftment, recipient informative alleles should be chosen to avoid stutter positions of donor alleles because of the difficulty in distinguishing small recipient DNA peaks in post-transplant samples from the stutter peaks that arise from upstream donor alleles. This restriction may necessitate screening six or more STRs before an informative allele that is not in a stutter peak position can be found. In cases where a recipient STR allele in a stutter position is the only available informative allele for post-transplant analysis, contribution from the stutter peak may be subtracted in the formula for calculating the percentage of recipient DNA. However, this correction decreases the accuracy of the STR analysis and raises the threshold of detection for recipient DNA. An unusually large or inconsistent stutter peak, such as that seen at the STR FGA locus for patient D, precludes the use of an informative allele in a stutter position. This study demonstrates that STR as well as VNTR markers are reliable tools for allogeneic BMT engraftment analysis. The decision whether to use STRs or VNTRs in the molecular diagnostics laboratory depends on cost, test volume, available instrumentation, and laboratory personnel. Commercial kits for STR analysis are well-suited for small to moderate sized laboratories with limited personnel for developing assays and maintaining quality control with their own test reagents. The cost of commercial STR kits, however, is relatively high. Larger reference laboratories may find it more cost efficient to develop their own fluorescently labeled VNTR or STR markers.
Although STRs are increasingly used for BMT engraftment analysis, neither guidelines nor standards have been established for performance of the assay or for reporting results. Furthermore, the precision and sensitivity of the STR assay for engraftment analysis are poorly defined. The precision, sensitivity, and accuracy of the assay should be carefully determined for each type of STR kit used on specific kinds of automated DNA sequencers. In addition, guidelines or standards for engraftment analysis need to be established by laboratory professionals and clinicians who direct allogeneic BMT programs.
